Silvia Moimas

Silvia Moimas has extensive work experience in the field of research, particularly in the areas of molecular cell biology, cardiovascular devices, cardiac and lung regeneration, and tumor angiogenesis. Silvia has held roles as a Scientist Molecular Cell Biology at Celerion since 2022, a Research Scientist at ETH Zürich from 2019 to 2022, a Research Scientist at ICGEB from 2017 to 2019, and a Postdoctoral Research Associate at Università degli Studi di Trieste from 2012 to 2016. Prior to that, they worked as a Postdoctoral Researcher and a PhD Student at ICGEB from 2004 to 2012, and as an Undergraduate Student at Leiden University from 2002 to 2003. In their roles, Silvia has been involved in various research activities such as developing strategies for cardiovascular device endothelialization, conducting high throughput screening approaches, and exploring gene therapy methods. Silvia has also focused on identifying and characterizing secreted factors related to cell differentiation and angiogenesis in cardiac and tumor cells, as well as studying immune cell populations and their role in vessel normalization.

Silvia Moimas holds a Doctor of Philosophy degree (PhD) in Molecular Medicine from Università degli Studi di Trieste, which they obtained from 2005 to 2009. Prior to that, they pursued a Master's degree in Pharmaceutical Chemistry and Technologies from the same university, attending from 1997 to 2003.

In addition to their formal education, Silvia Moimas has also obtained two certifications. In April 2022, they completed the Drug Development Product Management Specialization from Coursera. Moreover, in February 2022, they obtained the ISO 13485 Foundations Course certification from Advisera Expert Solutions Ltd.